Asset Details
Do you wish to reserve the book?
Pravastatin for the prevention of recurrent hypertensive disorders of pregnancy: study protocol for a randomized, open-label, parallel-group, three-arm trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pravastatin for the prevention of recurrent hypertensive disorders of pregnancy: study protocol for a randomized, open-label, parallel-group, three-arm trial
Do you wish to request the book?
Pravastatin for the prevention of recurrent hypertensive disorders of pregnancy: study protocol for a randomized, open-label, parallel-group, three-arm trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pravastatin for the prevention of recurrent hypertensive disorders of pregnancy: study protocol for a randomized, open-label, parallel-group, three-arm trial
2025
Overview
Background
Hypertensive disorders of pregnancy lead to a critically ill maternal/fetal state due to maternal organ failure and fetal dysfunction related to placental abruption or impaired placental circulation. No treatment with established efficacy for hypertensive disorders of pregnancy is currently available, and delivery is the only definitive treatment. This article describes the study protocol for a trial that aims to evaluate whether early pravastatin treatment is effective in preventing hypertensive disorders of pregnancy.
Methods
A randomized, open-label, parallel-group, three-arm trial will be conducted with aspirin administered as the baseline treatment across all groups. Pregnant women with a history of hypertensive disorders of pregnancy who are at high risk of developing hypertensive disorders of pregnancy will be recruited from four recruitment sites in Japan. The three interventions of the study comprise oral pravastatin 5 mg once daily with oral bayaspirin 100 mg once daily, oral pravastatin 10 mg once daily with oral bayaspirin 100 mg once daily, and oral bayaspirin 100 mg once daily alone. The primary outcome measure is the incidence of hypertension during pregnancy. The secondary outcome measures include incidence rates of preeclampsia and gestational hypertension, maternal serum soluble fms-like tyrosine kinase-1/placental growth factor ratio, as well as soluble fms-like tyrosine kinase-1 and placental growth factor levels, whether the mother is proteinuric, placental weight, umbilical cord blood lipid profile, the incidence of hypertensive disorders of pregnancy-related complications (placental abruption, hemolysis, elevated liver enzymes, and low platelet count syndrome, and eclampsia), week at diagnosis of hypertensive disorders of pregnancy, incidence of severe hypertensive disorders of pregnancy, and neonatal outcomes (birth weight, percentage of small for gestational age neonates, neonatal intensive care unit admission rate, and auditory brainstem response).
Discussion
The results of this study are expected to have wide-ranging implications given the effects of hypertensive disorders of pregnancy on long-term maternal and child health, as well as health economics.
Trial registration
Japan Registry of Clinical Trials (Trial ID: jRCTs031230067; registered May 11, 2023;
https://jrct.mhlw.go.jp/en-latest-detail/jRCTs031230067
).
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Adult
/ Aspirin
/ Children
/ Diseases
/ Efficacy
/ Female
/ Fetuses
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
/ Hypertension, Pregnancy-Induced - blood
/ Hypertension, Pregnancy-Induced - diagnosis
/ Hypertension, Pregnancy-Induced - epidemiology
/ Hypertension, Pregnancy-Induced - prevention & control
/ Hypertensive disorders of pregnancy
/ Kinases
/ Medicine
/ Multicenter Studies as Topic
/ Outcomes
/ Placenta Growth Factor - blood
/ Pravastatin - administration & dosage
/ Pravastatin - adverse effects
/ Pre-Eclampsia - prevention & control
/ Randomized Controlled Trials as Topic
/ Relapse
/ Safety
/ Secondary Prevention - methods
/ Statins
/ Statistics for Life Sciences
